Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy
- 1 June 2007
- journal article
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 13 (6) , 579-585
- https://doi.org/10.1111/j.1469-0691.2007.01693.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infectionsInternational Journal of Antimicrobial Agents, 2006
- Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosaClinical Microbiology & Infection, 2005
- Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, ColombiaJournal of Clinical Microbiology, 2004
- Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000)Diagnostic Microbiology and Infectious Disease, 2002
- Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?Clinical Infectious Diseases, 2002
- Of Pseudomonas, porins, pumps and carbapenemsJournal of Antimicrobial Chemotherapy, 2001
- Resistance Patterns Among Nosocomial PathogensChest, 2001
- Carbapenems and Monobactams: Imipenem, Meropenem, and AztreonamMayo Clinic Proceedings, 1999
- The Pharmacodynamics of β‐LactamsClinical Infectious Diseases, 1998